REFERENCES
- Duggan D J, Bittner M, Chen Y, et al. Expression profiling using cDNA microarrays. Nat Genet. 1999; 21: 10–14, [PUBMED], [INFOTRIEVE], [CSA]
- Kohlmann A, Schoch C, Schnittger S, et al. Molecular characterization of acute leukemias by use of microarray technology. Genes Chromosomes Cancer. 2003; 37: 396–405, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Alizadeh A A, Eisen M B, Davis R E, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403: 503–511, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Yagi T, Morimoto A, Eguchi M, et al. Identification of a gene expression signature associated with pediatric AML prognosis. Blood. 2003; 102: 1849–1856, Epub 8 May 03[PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ohali A, Avigad S, Zaizov R, et al. Prediction of high risk Ewing's sarcoma by gene expression profiling. Oncogene. 2004; 23: 8997–9006, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hasle H, Clemmensen I H, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. 2000; 355: 165–169, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Zipursky A, Brown E J, Christensen H, et al. Transient myeloproliferative disorder (transient leukemia) and hematologic manifestations of Down syndrome. Clin Lab Med. 1999; 19: 157–167, vii[PUBMED], [INFOTRIEVE], [CSA]
- Kojima S, Sako M, Kato K, et al. An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome. Leukemia. 2000; 14: 786–791, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Athale U H, Razzouk B I, Raimondi S C, et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood. 2001; 97: 3727–3732, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Leith C P, Kopecky K J, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997; 89: 3323–3329, [PUBMED], [INFOTRIEVE], [CSA]
- Campos L, Rouault J P, Sabido O, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993; 81: 3091–3096, [PUBMED], [INFOTRIEVE], [CSA]
- Kohler T, Schill C, Deininger M W, et al. High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML). Leukemia. 2002; 16: 22–29, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Sato T, Fuse A, Eguchi M, et al. Establishment of a human leukaemic cell line (CMK) with megakaryocytic characteristics from a Down's syndrome patient with acute megakaryoblastic leukaemia. Br J Haematol. 1989; 72: 184–190, [PUBMED], [INFOTRIEVE], [CSA]
- Ogura M, Morishima Y, Ohno R, et al. Establishment of a novel human megakaryoblastic leukemia cell line, MEG- 01, with positive Philadelphia chromosome. Blood. 1985; 66: 1384–1392, [PUBMED], [INFOTRIEVE], [CSA]
- Mariani T J, Budhraja V, Mecham B H, et al. A variable fold change threshold determines significance for expression microarrays. FASEB J. 2003; 17: 321–323, [PUBMED], [INFOTRIEVE], [CSA]
- Guan K L, Jenkins C W, Li Y, et al. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev. 1994; 8: 2939–2952, [PUBMED], [INFOTRIEVE], [CSA]
- Kulkarni M S, Daggett J L, Bender T P, et al. Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis. Leukemia. 2002; 16: 127–134, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Drexler H G. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia. 1998; 12: 845–859, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Duan H, Dixit V M. RAIDD is a new ‘death’ adaptor molecule. Nature. 1997; 385: 86–89, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ahmad M, Srinivasula S M, Wang L, et al. CRADD, a novel human apoptotic adaptor molecule for caspase-2, and FasL/tumor necrosis factor receptor-interacting protein RIP. Cancer Res. 1997; 57: 615–619, [PUBMED], [INFOTRIEVE], [CSA]
- Yoshioka K, Yamamoto S, Moriguchi N, et al. Overexpression of bcl-2 in transient abnormal myelopoiesis associated with Down syndrome. Ann Hematol. 2000; 79: 319–321, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Min Y H, Lee S, Lee J W, et al. Expression of Fas antigen in acute myeloid leukaemia is associated with therapeutic response to chemotherapy. Br J Haematol. 1996; 93: 928–930, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ravandi F, Kantarjian H M, Talpaz M, et al. Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Cancer. 2001; 91: 1964–1972, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Vorwerk P, Wex H, Hohmann B, et al. Expression of components of the IGF signalling system in childhood acute lymphoblastic leukaemia. Mol Pathol. 2002; 55: 40–45, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wex H, Vorwerk P, Mohnike K, et al. Elevated serum levels of IGFBP-2 found in children suffering from acute leukaemia is accompanied by the occurrence of IGFBP-2 mRNA in the tumour clone. Br J Cancer. 1998; 78: 515–520, [PUBMED], [INFOTRIEVE], [CSA]
- Mohnike K L, Kluba U, Mittler U, et al. Serum levels of insulin-like growth factor-I, -II and insulin-like growth factor binding proteins-2 and -3 in children with acute lymphoblastic leukaemia. Eur J Pediatr. 1996; 155: 81–86, [PUBMED], [INFOTRIEVE], [CSA]